An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.